Icagen/J&J Sickle Cell Disease Treatment Hits Phase III Snag
This article was originally published in The Pink Sheet Daily
Executive Summary
An independent data monitoring committee recommends Phase III enrollment continue for ICA-17043, but only for patients on concurrent hydroxyurea therapy.